What is the relationship between Dexamethasone and Myelom?
The relationship between dexamethasone and myeloma is that dexamethasone is often used as the only treatment or as part of a combined treatment for the condition. Studies have shown that steroid treatment increases the effects of common chemotherapeutic drugs. This has led to drugs such as Dexamethasone to be used in combination with other treatments such as thalidomide. High doses of dexamethasone collected separately can actually kill myeloma cells and is considered to be the most effective treatment of the condition. The main effect of the drug also reduces swelling around tumors and thus relieves pain.
Some of the pain associated with myeloma can be fought using steroid treatment. Dexamethasone is a synthetic adrenocortical steroid, which means it is an artificial form of steroids produced naturally in the adrenal glands. The main effect of the drug is inhibition of cytokines that control inflammation in the body. In patients with myeloma, areas of concentrated myeloma cells are often swollen and inflamed. By stopping cytokinesDexamethasone reduces swelling and reduces myeloma pain.
Dexamethasone and myeloma are connected because the drug can treat the condition in high doses. The international myeloma foundation identified Dexamethasone as the most effective only treatment of the condition. Studies have confirmed that patients taking a high dose of medicine for myeloma will survive 86 percent of the time. Sometimes the medicine can also cause myeloma to go into remission. The only problem with treatment in this way is increased adverse effects of risk.
The relationship between dexamethasone and myeloma means that it is often used as part of a combined treatment. Research has shown that steroid treatment can actually increase the efficacy of chemotherapy drugs. This allows other drugs to kill more cancer cells than it would be possible if they were raised separately. Dexamethasone and myelomfor the condition.
Research focused on the effects on myeloma of smaller doses of dexamethasone in combination with other drugs. After one year, patients with lower drugs survive in combination with a different treatment of around 96 percent of the time. A lower dose would reduce the risk of side effects related to dexamethasone and myeloma. Positive findings, such as this challenge, commonly argued that cancer should be treated with a maximum tolerable dose of drug.